Mechanisms of Drug-Induced hERG Cardiotoxicity

30 concepts22 papers1 proposal

Every time a new drug candidate is designed—whether it is an antihistamine, an antimalarial, or a cancer therapeutic—it must pass a strict cardiovascular safety gauntlet. The primary reason for this hurdle is a single protein found in cardiac muscle cells: the hERG (human ether-à-go-go-related gene) potassium channel.

When a non-cardiac drug accidentally blocks this channel, it can disrupt the heart's electrical rhythm, causing acquired Long QT Syndrome (LQTS) and potentially fatal ventricular arrhythmias. Understanding why this channel is so vulnerable, how different drugs disrupt it, and how we can predict this toxicity is one of the most critical challenges in modern drug discovery.

The Achilles' Heel of Cardiac Repolarization

To understand why hERG channel inhibition is so dangerous, we have to look at the cardiac action potential—the electrical cycle that coordinates every heartbeat.

Voltage
  ^      2. Plateau Phase (Ca2+ influx)
  |       /-----------\
  |      /             \
  |     /               \  3. Repolarization (K+ efflux via hERG)
  |    /                 \
  |   /                   \___________
  +------------------------------------> Time
     0. Depolarization

A normal heartbeat begins with a rapid influx of positive ions (sodium and calcium), which depolarizes the cardiac cell and causes it to contract. To relax and prepare for the next beat, the cell must reset its electrical potential by pumping positive potassium ions back out. The hERG channel is responsible for the rapid delayed rectifier potassium current ($I_{Kr}$), which drives this crucial repolarization phase.

If a drug blocks the hERG channel, potassium ions cannot escape efficiently. This stalls the repolarization process, stretching out the action potential duration. On an electrocardiogram (ECG), this delay manifests as a prolonged QT interval. When the electrical reset is delayed too long, it can trigger spontaneous, premature electrical firings known as early afterdepolarizations. These localized misfires can degenerate into a chaotic, life-threatening polymorphic ventricular tachycardia known as Torsades de Pointes.

The Anatomy of a Blockade: Direct vs. Indirect Disruption

Drugs can compromise hERG channel function through two distinct mechanisms: acute physical blockade or chronic expression failure.

Direct Pore Blockade

The hERG channel is structurally unique and notoriously "promiscuous"—it binds to an incredibly diverse array of chemical shapes. As Eunyong Chung et al. demonstrated in their study on the calcium channel blocker nicardipine, many drugs exert cardiotoxicity by binding directly inside the channel's central cavity. The authors identified that nicardipine interacts specifically with the F656 residue within the pore, physically plugging the channel and preventing potassium ions from passing through (Inhibitory Effect of Nicardipine on hERG Channel).

Chronic Expression and Trafficking Failure

Other compounds do not just plug the channel; they systematically reduce the number of functional channels present on the cell surface. This indirect cardiotoxicity can happen via altered gene expression or accelerated protein degradation:

Why Screening Paradigms Must Adapt

As the pharmaceutical industry transitions from traditional small molecules to novel therapeutic modalities, standard safety assays are beginning to fail.

Historically, hERG safety was evaluated using short-term, high-throughput electrophysiology assays, where a drug was applied to a cell for a few minutes to see if the current dropped. However, Yusheng Qu et al. revealed that these short-incubation assays are fundamentally blind to the risks posed by oligonucleotide therapeutics, such as siRNAs. Because oligonucleotides often affect channel synthesis and trafficking rather than direct pore binding, they require incubation periods of up to 48 hours to manifest their inhibitory effects (Time Is a Critical Factor When Evaluating Oligonucleotide Therapeutics in hERG Assays).

Furthermore, looking at hERG in isolation can mask risks that emerge in diseased tissue. For instance, Masahiko Nishimoto et al. demonstrated that the antihistamine astemizole slows electrical conduction more severely in damaged, ischemic heart tissue than in healthy tissue. This occurs because the drug acts on multiple ion channels simultaneously, creating a synergistic breakdown of cardiac rhythm that single-channel, healthy-cell assays fail to capture (Effects of Astemizole on Ventricular Activation Delay and RT Intervals in a Canine Myocardial Infarction Model.).

Predictive Safety: AI and Virtual Hearts

Because undetected cardiotoxicity is a primary driver of clinical trial failures (Ao Li et al., Low-dimensional materials for intracellular electrophysiology: advances from synthesis to applications), researchers are turning to computational models to flag dangerous compounds before they ever enter a wet lab.

Machine Learning Classifiers

Instead of running expensive patch-clamp experiments on millions of candidate molecules, researchers use machine learning to map chemical structures directly to toxicity risks. Guo-Wei Wei 0001 developed an AI model utilizing topological Laplacian embeddings to screen the DrugBank database, successfully flagging 227 potential hERG blockers out of over 8,000 compounds (Virtual screening of DrugBank database for hERG blockers using topological Laplacian-assisted AI models). Similarly, Srijit Seal et al. built public classifiers using the FDA's DICTrank dataset, proving that combining basic physicochemical properties with biological annotations yields highly accurate predictions of real-world pro-arrhythmic risk (Insights into Drug Cardiotoxicity from Biological and Chemical Data: The First Public Classifiers for FDA Drug-Induced Cardiotoxicity Rank).

Multiscale In Silico Modeling

To bridge the gap between a molecular interaction and a whole-organ disaster, researchers use multiscale computer simulations.

[ Chemical Structure ] 
         │  (AI / Molecular Docking)
         ▼
[ hERG Pore Binding / Conductance Drop ] 
         │  (Cellular Action Potential Models)
         ▼
[ Prolonged QT Interval / EADs ] 
         │  (3D Virtual Heart Simulation)
         ▼
[ Ventricular Arrhythmia Risk ]

By plugging a drug's specific channel-binding kinetics into mathematical models of cardiac tissue, researchers can simulate how cellular changes propagate across a 3D virtual heart. For example, Yacong Li et al. used these in silico mechanisms to map out exactly how arsenic trioxide alters tissue-level electrical timing to cause sudden cardiac arrest (In silico mechanisms of arsenic trioxide-induced cardiotoxicity).

By combining these advanced computational screens with an understanding of chronic trafficking pathways, modern drug discovery can systematically design out hERG liability, ensuring that potent new therapies save lives without endangering hearts.

Key Foundational Work

Kv1.3-Blocking 5-Phenylalkoxypsoralens: A New Class of Immunomodulators (2004) — contributed 1 concept elements to this direction.
Effects of Astemizole on Ventricular Activation Delay and RT Intervals in a Canine Myocardial Infarction Model. (1997) — contributed 1 concept elements to this direction.
History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_drug_induced_cardiotoxicity_38856b5e,
  title = {drug-induced cardiotoxicity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/drug-induced-cardiotoxicity/rdr_38856b5e40c24b2abaaeb0862788e925},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_drug_induced_cardiotoxicity_38856b5e_v1,
  title = {drug-induced cardiotoxicity},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/drug-induced-cardiotoxicity/rdr_38856b5e40c24b2abaaeb0862788e925/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake